NO20032938L - Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler - Google Patents

Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler

Info

Publication number
NO20032938L
NO20032938L NO20032938A NO20032938A NO20032938L NO 20032938 L NO20032938 L NO 20032938L NO 20032938 A NO20032938 A NO 20032938A NO 20032938 A NO20032938 A NO 20032938A NO 20032938 L NO20032938 L NO 20032938L
Authority
NO
Norway
Prior art keywords
well
quaternary ammonium
ammonium compounds
muscarinic agents
trifluoromethyl
Prior art date
Application number
NO20032938A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032938D0 (no
Inventor
Ivan Richards
Sergey G Wolfson
Sue K Cammarata
Patrick J Lennon
Craig D Wegner
Michael Hawley
Mark P Warchol
Mark J Kontny
Walter Morozowich
Karen P Kolbasa
Malcolm W Moon
Dominique Bonafoux
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20032938D0 publication Critical patent/NO20032938D0/no
Publication of NO20032938L publication Critical patent/NO20032938L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/66—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20032938A 2001-10-26 2003-06-26 Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler NO20032938L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34893001P 2001-10-26 2001-10-26
US36197902P 2002-03-06 2002-03-06
US39152102P 2002-06-25 2002-06-25
PCT/US2002/034529 WO2003035599A1 (fr) 2001-10-26 2002-10-25 Composes d'ammonium quaternaire

Publications (2)

Publication Number Publication Date
NO20032938D0 NO20032938D0 (no) 2003-06-26
NO20032938L true NO20032938L (no) 2003-08-25

Family

ID=27407868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032938A NO20032938L (no) 2001-10-26 2003-06-26 Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler

Country Status (16)

Country Link
US (2) US6890920B2 (fr)
EP (1) EP1461306B1 (fr)
JP (1) JP3981357B2 (fr)
AT (1) ATE418534T1 (fr)
BR (1) BR0206207A (fr)
CA (1) CA2464223C (fr)
CY (1) CY1109898T1 (fr)
DE (1) DE60230546D1 (fr)
DK (1) DK1461306T3 (fr)
ES (1) ES2315425T3 (fr)
MX (1) MXPA04003865A (fr)
MY (1) MY130316A (fr)
NO (1) NO20032938L (fr)
PT (1) PT1461306E (fr)
SG (1) SG168451A1 (fr)
WO (1) WO2003035599A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
WO2003035599A1 (fr) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Composes d'ammonium quaternaire
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
ATE425744T1 (de) * 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
CA2522102A1 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Composes d'ammonium quaternaire et leur utilisation comme agents antimuscariniques
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
CA2522666A1 (fr) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Polytherapies
MXPA05011509A (es) 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.
CA2537103C (fr) * 2003-11-04 2010-01-19 Shire Laboratories, Inc. Forme dosifiee quotidienne de trospium
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (fr) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions et leurs utilisations, et preparations desdites compositions
JP2007530451A (ja) * 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006066931A1 (fr) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Procede de preparation de 3-(2-hydroxy-5-methylphenyl)-n,n-diisopropyl-3-phenylpropylamine
JP2009537585A (ja) * 2006-05-24 2009-10-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のための新規医薬組成物
EP1908502A1 (fr) * 2006-10-02 2008-04-09 Koninklijke Philips Electronics N.V. Système modulaire de carreaux interactifs
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
WO2008103426A1 (fr) * 2007-02-23 2008-08-28 Theravance, Inc. Composés de diphénylméthyle d'ammonium quartenaire utilisés comme antagonistes de récepteur muscarinique
EP2146957B1 (fr) 2007-04-24 2013-06-12 Theravance, Inc. Composés d'ammonium quaternaire utiles en tant qu'antagonistes des récepteurs muscariniques
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
WO2009152171A1 (fr) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Composés bêta agonistes liés à des corticostéroïdes en vue d'une utilisation en thérapie
US20110171274A1 (en) * 2008-07-21 2011-07-14 Actavis Group Ptc Ehf Fesoterodine Substantially Free of Dehydroxy Impurity
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
CN110845357B (zh) * 2019-11-22 2022-09-30 华东理工大学 季铵盐型酰肼化合物及由其制备的季铵盐型腙类化合物与应用
WO2021260441A1 (fr) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations comprenant du (5-[3-(3-hydroxyphénoxy)azétidin-1-yl]-5-méthyl-2,2-diphénylhexanamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE106643C (fr)
US2592191A (en) * 1949-09-16 1952-04-08 Sterling Drug Inc Quaternary ammonium salts of nu-(3, 3-diphenylpropyl) pyrrolidine
NL267508A (fr) 1960-07-26
NL6717123A (fr) * 1966-12-29 1968-07-01
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
IL91377A (en) * 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5492933A (en) 1993-10-08 1996-02-20 Sepracor, Inc. Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
AU7971394A (en) 1993-10-08 1995-05-04 Sepracor, Inc. Method for treating urinary incontinence using optically pure s-terodiline
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
JP2004512531A (ja) 2000-10-26 2004-04-22 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 電子デバイス
WO2003035599A1 (fr) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Composes d'ammonium quaternaire
CA2522102A1 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Composes d'ammonium quaternaire et leur utilisation comme agents antimuscariniques
MXPA05011509A (es) * 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.

Also Published As

Publication number Publication date
MY130316A (en) 2007-06-29
CY1109898T1 (el) 2014-09-10
WO2003035599A1 (fr) 2003-05-01
EP1461306A1 (fr) 2004-09-29
US6890920B2 (en) 2005-05-10
MXPA04003865A (es) 2004-07-08
ATE418534T1 (de) 2009-01-15
US20030158176A1 (en) 2003-08-21
US20050148672A1 (en) 2005-07-07
JP2005524605A (ja) 2005-08-18
DE60230546D1 (de) 2009-02-05
CA2464223C (fr) 2009-05-26
JP3981357B2 (ja) 2007-09-26
SG168451A1 (en) 2011-02-28
CA2464223A1 (fr) 2003-05-01
EP1461306B1 (fr) 2008-12-24
ES2315425T3 (es) 2009-04-01
DK1461306T3 (da) 2009-03-09
NO20032938D0 (no) 2003-06-26
US7439397B2 (en) 2008-10-21
PT1461306E (pt) 2009-04-01
BR0206207A (pt) 2003-12-23

Similar Documents

Publication Publication Date Title
NO20032938L (no) Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler
PA8546301A1 (es) Resolucion de sal quiral
BR122012009534C8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1651621T3 (da) 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
BRPI0411268C8 (pt) Processo para a preparação de compostos 3-aril butil-amina substituído
DE602007004494D1 (de) Herstellung von (2r,3r)-3-(3-methoxyphenyl)-n,n,2- trimethylpentanamin
NO20041339L (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
ECSP056220A (es) Nuevos compuestos 2-piridiniletilbenzamida
NO20061412L (no) Terapi av okulaere foretyrrelser
SE0702536L (sv) Kvartära ammoniumföreningar med lång kedja som träbehandlingsmedel
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
BRPI0507847A (pt) processo para a preparação de um composto, e, composto
DE602004014806D1 (de) Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
DK1210326T3 (da) Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
ITMI20050249A1 (it) Procedimento per la preparazione di tolterodina
BR9915868A (pt) Processo para a decomposição de tramadol
BRPI0412721A (pt) processo para preparar bromidrato de eletriptano alfa-polimórfico
AR051991A1 (es) Procedimiento para la preparacion de anilinas
BRPI0408453A (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BR9916382A (pt) Processo para a preparação de um composto
HRP20030653B1 (en) Novel benzoylguanidine salt
BRPI0614104A2 (pt) compostos, processo para preparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application